Profile data is unavailable for this security.
About the company
Formosa Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the development of early drug candiate and pre-clinical drug products. The Company also conducts the research and development of nanotechnology platform and dosage form design, and uses the patented nano platform to overcome the challenges of low dissociation rate and poor bioavailability in the development of pharmaceutical dosage forms. In the research and development projects, the ophthalmic drug APP13007 has entered the phase III clinical trial stage, and its indications are anti-ocular postoperative inflammation, and its main appeal is to reduce postoperative inflammation and pain. TSY-0110 has entered the preclinical stage to develop antibody-drug conjugate (ADC) to cure breast cancer. The innovative small molecule compound MPT0E028 has completed the first phase of clinical trials and is expected to be used in the field of anti-cancer therapy.
- Revenue in TWD (TTM)133.70m
- Net income in TWD-298.43m
- Incorporated2010
- Employees--
- LocationFormosa Pharmaceuticals Inc8F-6, No. 57, Fuxing North RoadTAIPEI 105TaiwanTWN
- Phone+886 227557659
- Fax+886 227553023
- Websitehttps://www.formosapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nang Kuang Pharmaceutical Co Ltd | 2.09bn | 110.65m | 4.35bn | 552.00 | 39.34 | 1.91 | 14.85 | 2.08 | 1.09 | 1.09 | 20.72 | 22.52 | 0.571 | 1.89 | 8.07 | -- | 3.02 | 6.75 | 4.47 | 9.64 | 33.14 | 34.77 | 5.28 | 12.22 | 0.6312 | 14.42 | 0.1587 | 82.74 | 10.81 | 6.92 | -43.63 | 14.41 | 19.51 | 10.76 |
| Sinphar Pharmaceutical Co Ltd | 3.01bn | 361.33m | 5.52bn | 984.00 | 14.18 | 1.64 | 9.38 | 1.83 | 2.15 | 2.15 | 17.93 | 18.61 | 0.4864 | 2.28 | 6.06 | -- | 5.71 | -0.0147 | 7.67 | -0.0203 | 39.02 | 37.49 | 11.74 | -0.0344 | 1.44 | 37.22 | 0.3599 | 79.70 | 3.72 | 5.98 | 67.01 | 111.88 | 3.31 | 58.49 |
| Cenra Inc | 8.87bn | 355.20m | 5.58bn | 1.40k | 31.45 | 1.50 | 7.96 | 0.6292 | 1.19 | 1.19 | 29.73 | 24.90 | 0.7027 | 2.22 | 5.63 | -- | 2.83 | 3.69 | 4.03 | 4.96 | 36.79 | 36.56 | 4.02 | 5.50 | 0.7959 | -- | 0.2943 | 52.77 | 1.40 | 2.50 | -32.51 | -2.72 | 3.57 | -8.97 |
| Formosa Pharmaceuticals Inc | 133.70m | -298.43m | 6.43bn | -- | -- | 5.65 | -- | 48.10 | -2.22 | -2.22 | 0.9963 | 7.54 | 0.0803 | -- | 1.61 | -- | -17.91 | -40.34 | -19.62 | -44.21 | 86.96 | -- | -223.16 | -2,488.28 | -- | -- | 0.0277 | -- | 2,270.49 | -- | 20.75 | -- | -42.98 | -- |
| Panion & BF Biotech Inc | 2.01bn | 101.27m | 7.95bn | 321.00 | 78.52 | 4.29 | 29.15 | 3.96 | 1.18 | 1.18 | 23.42 | 21.62 | 0.6185 | 1.73 | 9.66 | -- | 3.12 | 4.08 | 4.82 | 5.63 | 52.66 | 52.37 | 5.04 | 5.93 | 0.8699 | 10.62 | 0.287 | 111.06 | -21.54 | 5.96 | -57.65 | -13.47 | 35.39 | -3.23 |
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 71.67k | 0.05% |
